Vertex Pharmaceuticals Incorporated
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Long-term Follow-up Study in Participants Who Received CTX001
- Conditions
- Beta-ThalassemiaSickle Cell AnemiaGenetic Diseases, InbornHemoglobinopathiesHematologic DiseasesThalassemiaSickle Cell Disease
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 160
- Registration Number
- NCT04208529
- Locations
- π¬π§
University College London Hospitals NHS Foundation Trust, London, United Kingdom
πΊπΈLucile Packard Children's Hospital, Palo Alto, California, United States
πΊπΈAnn & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT04183790
- Locations
- πΊπΈ
Children's Hospital of Orange County, Orange, California, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
πΊπΈAnn & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT04167345
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUniversity of California Davis Medical Center, Sacramento, California, United States
πΊπΈNational Jewish Health, Denver, Colorado, United States
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 176
- Registration Number
- NCT04105972
- Locations
- π¦πΊ
The Prince Charles Hospital, Chermside, Australia
π¦πΊInstitute for Respiratory Health, Nedlands, Australia
π¦πΊPerth Children's Hospital, Nedlands, Australia
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 271
- Registration Number
- NCT04058353
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈBanner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈMiller Children's Hospital / Long Beach Memorial, Long Beach, California, United States
VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT04058210
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 251
- Registration Number
- NCT04058366
- Locations
- πΊπΈ
Banner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈMiller Children's Hospital / Long Beach Memorial, Long Beach, California, United States
πΊπΈStanford University, Palo Alto, California, United States
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 458
- Registration Number
- NCT04043806
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 87
- Registration Number
- NCT03912233
- Locations
- πΊπΈ
Keck Medical Center of University of Southern California, Los Angeles, California, United States
πΊπΈKaiser Permanente, Oakland, California, United States
πΊπΈUniversity of Kentucky., Lexington, Kentucky, United States
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 77
- Registration Number
- NCT03911713
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈBanner University of Arizona Medical Center, Tucson, Arizona, United States
πΊπΈMiller Children's Hospital / Long Beach Memorial, Long Beach, California, United States